Clinical Trial Update: Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac [Phase 1]

View source ↗

Summary

This is a completed Phase 1 trial evaluating a yttrium-90 radiolabeled anti-Tac antibody in patients with cutaneous T-cell lymphoma and adult T-cell leukemia/ly…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• T-cell Leukemia Lymphoma

Drugs mentioned

• Daclizumab (Yttrium-90 radiolabeled anti-Tac) (daclizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Leukemia, T-Cell, Lymphoma, T-Cell, Cutaneous | Phase 1 | Status: COMPLETED